Skip to main content

Table 2 Demographic information for patients of the analysis cohort

From: Urinary chitinase 3-like protein 1 for early diagnosis of acute kidney injury: a prospective cohort study in adult critically ill patients

 

All patients

AKISCr/UO stage ≥ 2a

No AKISCr/UO stage ≥ 2a

P value

All patients

181 (100 %)

6 (3.3 %)

175 (96.7 %)

NA

(1.5–7.0 %)

(93.0–98.5 %)

Baseline characteristics

Sex, male

114 (63.0 %)

4 (66.7 %)

110 (62.9 %)

1.000

(55.7–69.7 %)

(30.0–90.3 %)

(55.5–69.7 %)

Ageb, y

60.0 (51.0–70.0)

70.5 (65.8–78.0)

59.0 (50.0–70.0)

0.040

Race, white

181 (100 %)

6 (100 %)

175 (100 %)

NA

(97.9–100 %)

(61.0–100 %)

(97.9–100 %)

Body mass index

24 (22–28)

25 (23–28)

24 (22–28)

0.594

Reference renal function

 SCr (mg/dl)

0.66 (0.52–0.79)

0.64 (0.55–0.69)

0.66 (0.51–0.79)

0.660

 eGFRMDRD (ml/min/1.73 m2)

119 (89–150)

120 (105–134)

119 (89–153)

0.975

 eGFRCKD-EPI (ml/min/1.73 m2)

102 (89–118)

98 (92–102)

103 (89–118)

0.392

Diabetes mellitus

   

0.787

 Type I

2 (1.1 %)

0 (0.0 %)

2 (1.1 %)

 

(0.3–3.9 %)

(0.0–39.0 %)

(0.3–4.1 %)

 Type II

11 (6.1 %)

0 (0.0 %)

11 (6.3 %)

 

(3.4–10.6 %)

(0.0–39.0 %)

(3.5–10.9 %)

Heart failure

   

1.000

 NYHA class I

179 (98.9 %)

6 (100 %)

173 (98.9 %)

 

(96.1–99.7 %)

(61.0–100 %)

(95.9–99.7 %)

 NYHA class II

2 (1.1 %)

0 (0.0 %)

2 (1.1 %)

 

(0.3–3.9 %)

(0.0–39.0 %)

(0.3–4.1 %)

 NYHA class III

0 (0.0 %)

0 (0.0 %)

0 (0.0 %)

 

(0.0–2.1 %)

(0.0–39.0 %)

(0.0–2.1 %)

 NYHA class IV

0 (0.0 %)

0 (0.0 %)

0 (0.0 %)

 

(0.0–2.1 %)

(0.0–39.0 %)

(0.0–2.1 %)

Myocardial infarction or cardiac arrestc

17 (9.4 %)

0 (0.0 %)

17 (9.7 %)

1.000

(5.9–14.5 %)

(0.0–39.0 %)

(6.2–15.0 %)

Malignancyc

17 (9.4 %)

1 (16.7 %)

16 (9.1 %)

0.451

(5.9–14.5 %)

(3.0–56.4 %)

(5.7–14.3 %)

ICU admission

Referred from

   

0.063

 Other hospital

42 (23.2 %)

0 (0.0 %)

42 (24.0 %)

 

(17.7–29.9 %)

(0.0–39.0 %)

(18.3–30.8 %)

 Emergency room

75 (41.4 %)

1 (16.7 %)

74 (42.3 %)

 

(34.5–48.7 %)

(3.0–56.4 %)

(35.2–49.7 %)

 Operating room

21 (11.6 %)

1 (16.7 %)

20 (11.4 %)

 

(7.7–17.1 %)

(3.0–56.4 %)

(35.8–50.3 %)

 Floor

43 (23.8 %)

4 (66.7 %)

39 (22.3 %)

 

(18.1–30.5 %)

(30.0–90.3 %)

(16.8–29.0 %)

Reason

   

0.038

 Medical

108 (59.7 %)

3 (50.0 %)

105 (60.0 %)

 

(52.4–66.5 %)

(18.8–81.2 %)

(52.6–67.0 %)

 Elective surgery

13 (7.2 %)

2 (33.3 %)

11 (6.3 %)

 

(4.2–11.9 %)

(9.7–70.0 %)

(3.5–10.9 %)

 Urgent surgery

60 (33.1 %)

1 (16.7 %)

59 (33.7 %)

 

(26.7–40.3 %)

(3.0–56.4 %)

(27.1–41.0 %)

First day of study

SOFA score (points)

9 (7–11)

11 (8–16)

9 (7–11)

0.189

Mechanical ventilation

122 (67.4 %)

5 (83.3 %)

117 (66.9 %)

0.665

(60.3–73.8 %)

(43.6–97.0 %)

(59.6–73.4 %)

Vasopressors

117 (64.6 %)

4 (66.7 %)

113 (64.6 %)

1.000

(57.4–71.2 %)

(30.0–90.3 %)

(57.2–71.3 %)

Infection

153 (84.5 %)

6 (100 %)

147 (84.0 %)

0.592

(78.6–89.1 %)

(61.0–100 %)

(77.8–88.7 %)

Infection ++d

122 (67.4 %)

6 (100 %)

116 (66.3 %)

0.179

(60.3–73.8 %)

(61.0–100 %)

(59.0–72.9 %)

Nephrotoxic drugs (before or at the first study day)

ACE inhibitors

25 (13.8 %)

1 (16.7 %)

24 (13.7 %)

0.596

(9.5–19.6 %)

(3.0–56.4 %)

(9.4–19.6 %)

ARBs

5 (2.8 %)

0 (0.0 %)

5 (2.9 %)

1.000

(1.2–6.3 %)

(0.0–39.0 %)

(1.2–6.5 %)

Iodinated contrast media

81 (44.8 %)

2 (33.3 %)

79 (45.1 %)

0.693

(37.7–52.0 %)

(9.7–70.0 %)

(38.0–52.5 %)

Aminoglycosides

6 (3.3 %)

0 (0.0 %)

6 (3.4 %)

1.000

(1.5–7.0 %)

(0.0–39.0 %)

(1.6–7.3 %)

Vancomycine

15 (8.3 %)

0 (0.0 %)

15 (8.6 %)

1.000

(5.1–13.2 %)

(0.0–39.0 %)

(5.3–13.7 %)

Diuretics

45 (24.9 %)

3 (50.0 %)

42 (24.0 %)

0.164

(19.1–31.6 %)

(18.8–81.2 %)

(18.3–30.8 %)

Tacrolimus

2 (1.1 %)

1 (16.7 %)

1 (0.6 %)

0.065

(0.3–3.9 %)

(3.0–56.4 %)

(0.1–3.2 %)

Cyclosporine

1 (0.6 %)

0 (0.0 %)

1 (0.6 %)

1.000

(0.1–3.1 %)

(0.0–39.0 %)

(0.1–3.2 %)

NSAIDs (chronic)

10 (5.5 %)

1 (16.7 %)

9 (5.1 %)

0.292

(3.0–9.9 %)

(3.0–56.4 %)

(2.7–9.5 %)

Corticosteroids (chronic)

24 (13.3 %)

1 (16.7 %)

23 (13.1 %)

0.580

(9.1–19.0 %)

(3.0–56.4 %)

(8.9–18.9 %)

  1. aWithin 12 h after enrollment (primary endpoint); based on the Kidney Disease | Improving Global Outcomes (KDIGO) serum creatinine (SCr) or urine output (UO) criteria for acute kidney injury (AKI). bDetermined at the first day of the study. cAt time of hospital or ICU admission. dSuspected bacterial infection, either leading to arterial hypotension or organ dysfunction, or leading to shock (Additional file 1: Table S4A). Data represent number (%) (95 % CI) and median (IQR) for categorical and continuous variables, respectively. ACE angiotensin converting enzyme, ARB angiotensin-II receptor blocker, CI confidence interval, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, eGFR estimated glomerular filtration rate, ICU intensive care unit, IQR interquartile range, MDRD Modification of Diet in Renal Disease, NSAID nonsteroidal anti-inflammatory drug, NYHA New York Heart Association, SOFA Sepsis-related Organ Failure Assessment
Back to article page

Critical Care

ISSN: 1364-8535